• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    UK Clinical Trials Market

    ID: MRFR/HS/48502-HCR
    200 Pages
    Garvit Vyas
    September 2025

    UK Clinical Trials Market Research Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Therapeutic Area (Oncology, Cardiology, Neurology, Infectious Diseases, Endocrinology) and By End Use (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    UK Clinical Trials Market Research Report — Global Forecast till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    UK Clinical Trials Market Summary

    The United Kingdom UK Clinical Trials market is projected to grow from 3.3 USD billion in 2024 to 4.8 USD billion by 2035.

    Key Market Trends & Highlights

    UK Clinical Trials Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 3.46 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 4.8 USD billion, indicating robust growth potential.
    • In 2024, the market is valued at 3.3 USD billion, reflecting the current investment landscape in clinical trials.
    • Growing adoption of innovative technologies due to increasing demand for efficient trial processes is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.3 (USD Billion)
    2035 Market Size 4.8 (USD Billion)
    CAGR (2025-2035) 3.46%

    Major Players

    Covance, Medpace, PPD, PRA Health Sciences, Celerion, Charles River Laboratories, Worldwide Clinical Trials, Wuxi AppTec, Syneos Health, PAREXEL International, ICON plc, CRF Health, Quintiles, IMS, KCR

    UK Clinical Trials Market Trends

    The UK Clinical Trials Market is undergoing notable changes which are a result of supportive policies, technological development, and increased emphasis on the patient’s experience. The UK government has taken steps to simplify the regulatory framework so that trials may start much earlier, but the safety considerations are not compromised. This regulatory framework improves the clinical research sponsorship competition from both domestic and international investors.

    The UK Clinical Trials Market has opportunities in the form of decentralized trials which can be conducted using telehealth and remote patient monitoring technologies. Such technologies provide better accessibility to a clinical trial and increase the diversity of the patients who can participate. The application of AI and data analytics in the design and management of clinical trials is yet another untapped opportunity. The utilization of these technologies will enable companies to improve the efficiency and accuracy of data generated during the trials.

    There has been a growing focus on the allied concepts of diversity and inclusivity during the execution of clinical trials in the UK. The shift in regulations aims to make trials more inclusive so they capture more relevant data which will increase the efficacy of the drugs for a wider population. Also, there is an increasing pattern of cooperation among the educational world, business, and healthcare services for the purpose of developing novel design techniques that improve the efficiency and effectiveness of research.

    All in all, these trends underscore the UK Clinical Trials Market as very active, where balanced policies, emerging technologies, and attention to diversity support tremendous progress in medical research and enhance the results for patients.

    UK Clinical Trials Market Drivers

    Market Segment Insights

    Get more detailed insights about UK Clinical Trials Market Research Report — Global Forecast till 2035

    Regional Insights

    Key Players and Competitive Insights

    The UK Clinical Trials Market is characterized by intense competition, with a diverse range of players vying for dominance in this sector aimed at advancing medical research, drug development, and therapeutic innovations. The market is influenced by various factors such as regulatory dynamics, technological advancements, and the rising demand for more efficient clinical trial methodologies. The competitive landscape is shaped by a mixture of established Contract Research Organizations (CROs), academic institutions, and biotech firms, all aiming to leverage their capabilities to attract pharmaceutical and biopharmaceutical sponsors.

    The adoption of patient-centric approaches and the integration of advanced technologies like artificial intelligence and real-time data analytics are becoming essential strategies for organizations working within this realm, setting the stage for advancements in trial efficiency and outcomes. Covance is a prominent player in the UK Clinical Trials Market, known for its extensive capabilities in drug development and commercialization services. The company has established a strong market presence, specializing in a wide range of therapeutic areas, which allows it to offer clients comprehensive solutions tailored to their specific needs.

    Covance's strengths lie in its vast experience, skilled workforce, and an extensive network that aids in the efficient execution of trials. By leveraging its integrated approach, including regulatory support, data management, and patient recruitment strategies, Covance has been able to maintain a competitive edge. The company's commitment to innovation and quality ensures that it remains a trusted partner for sponsors seeking to expedite their drug development processes while adhering to regulatory standards. Medpace has also carved a significant niche in the UK Clinical Trials Market by offering streamlined services that encompass all stages of clinical development.

    The company’s key offerings include clinical trial management, regulatory consulting, and data management, which are critical for timely and effective study execution. Medpace's strong emphasis on therapeutic expertise, particularly in areas such as oncology, cardiology, and central nervous system disorders, enhances its ability to attract and retain clients in the highly competitive UK market. The company has bolstered its market presence through strategic mergers and acquisitions, which have expanded its operational capabilities and geographic reach.

    Medpace's strengths lie in its commitment to high-quality service, personalized approach to client collaboration, and innovative solutions, positioning it as an influential player in the UK Clinical Trials landscape.

    Key Companies in the UK Clinical Trials Market market include

    Industry Developments

    The UK Clinical Trials Market has seen notable developments recently, particularly in response to regulatory changes and technological advancements. In September 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) introduced new guidelines aimed at streamlining trial approvals, which is expected to enhance the efficiency of conducting clinical studies across companies such as Covance, PPD, and ICON plc. Additionally, Pra Health Sciences and Medpace are actively engaging in discussions to expand their service offerings, aligning with ongoing shifts towards patient-centric trials.

    In terms of mergers and acquisitions, Celerion announced plans to acquire a smaller firm focused on biomarker analysis in August 2023, enhancing its capabilities within the UK market. Moreover, Syneos Health's acquisition of an analytics company in June 2023 has strengthened its offerings in Real World Evidence, responding to growing demand from sponsors. The overall market valuation is on an upward trend, accelerated by increased investments in Research and Development and innovative trial designs.

    Major contract research organizations (CROs) are adapting to these dynamics, which has significantly impacted the competitive landscape within the UK Clinical Trials domain over the past couple of years.

    Market Segmentation

    Clinical Trials Market Phase Outlook

    • Phase I
    • Phase II
    • Phase III
    • Phase IV

    Clinical Trials Market End Use Outlook

    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research Organizations

    Clinical Trials Market Study Design Outlook

    • Interventional
    • Observational
    • Expanded Access

    Clinical Trials Market Therapeutic Area Outlook

    • Oncology
    • Cardiology
    • Neurology
    • Infectious Diseases
    • Endocrinology

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 3.16(USD Billion)
    MARKET SIZE 2024 3.3(USD Billion)
    MARKET SIZE 2035 4.8(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 3.467% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Covance, Medpace, PPD, PRA Health Sciences, Celerion, Charles River Laboratories, Worldwide Clinical Trials, Wuxi AppTec, Syneos Health, PAREXEL International, ICON plc, CRF Health, QuintilesIMS, KCR
    SEGMENTS COVERED Phase, Study Design, Therapeutic Area, End Use
    KEY MARKET OPPORTUNITIES Increased investment in digital health, Growth in rare disease trials, Expanding patient recruitment technologies, Enhanced regulatory support initiatives, Rising demand for real-world evidence
    KEY MARKET DYNAMICS regulatory compliance, patient recruitment challenges, technological advancements, cost management, increasing competition
    COUNTRIES COVERED UK

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Leave a Comment

    FAQs

    What is the expected market size of the UK Clinical Trials Market in 2024?

    The UK Clinical Trials Market is expected to be valued at approximately 3.3 billion USD in 2024.

    What is the projected market value of the UK Clinical Trials Market by 2035?

    By 2035, the UK Clinical Trials Market is projected to reach a value of about 4.8 billion USD.

    What is the expected CAGR for the UK Clinical Trials Market from 2025 to 2035?

    The anticipated compound annual growth rate for the UK Clinical Trials Market from 2025 to 2035 is approximately 3.467 percent.

    Which phase of clinical trials has the largest market share in 2024?

    Phase III of the clinical trials is expected to hold the largest market share, valued at about 1.2 billion USD in 2024.

    What will be the value of Phase I clinical trials by 2035?

    Phase I clinical trials are projected to be valued at around 1.4 billion USD by 2035.

    Who are the key players in the UK Clinical Trials Market?

    Major players in the UK Clinical Trials Market include companies like Covance, Medpace, PPD, and PRA Health Sciences.

    What is the expected value of Phase IV clinical trials in 2024?

    Phase IV clinical trials are expected to be valued at approximately 0.3 billion USD in 2024.

    What market growth rate is anticipated for Phase II clinical trials from 2025 to 2035?

    The market for Phase II clinical trials is expected to grow to about 1.1 billion USD by 2035, indicating significant growth.

    What market trends are driving the growth of the UK Clinical Trials Market?

    Emerging trends driving growth include advancements in technology and an increasing demand for personalized medicine.

    How is the competitive landscape of the UK Clinical Trials Market structured?

    The competitive landscape features a mix of global and local players, highlighting a diverse range of service offerings in the market.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. UK Clinical Trials Market, BY Phase (USD Billion)
    45. Phase I
    46. Phase II
    47. Phase III
    48. Phase IV
    49. UK Clinical Trials Market, BY Study Design (USD Billion)
    50. Interventional
    51. Observational
    52. Expanded Access
    53. UK Clinical Trials Market, BY Therapeutic Area (USD Billion)
    54. Oncology
    55. Cardiology
    56. Neurology
    57. Infectious Diseases
    58. Endocrinology
    59. UK Clinical Trials Market, BY End Use (USD Billion)
    60. Pharmaceutical Companies
    61. Biotechnology Companies
    62. Contract Research Organizations
    63. Competitive Landscape
    64. Overview
    65. Competitive Analysis
    66. Market share Analysis
    67. Major Growth Strategy in the Clinical Trials Market
    68. Competitive Benchmarking
    69. Leading Players in Terms of Number of Developments in the Clinical Trials Market
    70. Key developments and growth strategies
    71. New Product Launch/Service Deployment
    72. Merger & Acquisitions
    73. Joint Ventures
    74. Major Players Financial Matrix
    75. Sales and Operating Income
    76. Major Players R&D Expenditure. 2023
    77. Company Profiles
    78. Covance
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Medpace
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. PPD
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. PRA Health Sciences
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. Celerion
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Charles River Laboratories
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. Worldwide Clinical Trials
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. Wuxi AppTec
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Syneos Health
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. PAREXEL International
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. ICON plc
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. CRF Health
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. QuintilesIMS
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. KCR
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. References
    163. Related Reports
    164. UK Clinical Trials Market SIZE ESTIMATES & FORECAST, BY PHASE, 2019-2035 (USD Billions)
    165. UK Clinical Trials Market SIZE ESTIMATES & FORECAST, BY STUDY DESIGN, 2019-2035 (USD Billions)
    166. UK Clinical Trials Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2035 (USD Billions)
    167. UK Clinical Trials Market SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD Billions)
    168. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    169. ACQUISITION/PARTNERSHIP
    170. MARKET SYNOPSIS
    171. UK CLINICAL TRIALS MARKET ANALYSIS BY PHASE
    172. UK CLINICAL TRIALS MARKET ANALYSIS BY STUDY DESIGN
    173. UK CLINICAL TRIALS MARKET ANALYSIS BY THERAPEUTIC AREA
    174. UK CLINICAL TRIALS MARKET ANALYSIS BY END USE
    175. KEY BUYING CRITERIA OF CLINICAL TRIALS MARKET
    176. RESEARCH PROCESS OF MRFR
    177. DRO ANALYSIS OF CLINICAL TRIALS MARKET
    178. DRIVERS IMPACT ANALYSIS: CLINICAL TRIALS MARKET
    179. RESTRAINTS IMPACT ANALYSIS: CLINICAL TRIALS MARKET
    180. SUPPLY / VALUE CHAIN: CLINICAL TRIALS MARKET
    181. CLINICAL TRIALS MARKET, BY PHASE, 2025 (% SHARE)
    182. CLINICAL TRIALS MARKET, BY PHASE, 2019 TO 2035 (USD Billions)
    183. CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2025 (% SHARE)
    184. CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019 TO 2035 (USD Billions)
    185. CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2025 (% SHARE)
    186. CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2019 TO 2035 (USD Billions)
    187. CLINICAL TRIALS MARKET, BY END USE, 2025 (% SHARE)
    188. CLINICAL TRIALS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    189. BENCHMARKING OF MAJOR COMPETITORS

    UK Clinical Trials Market Segmentation

     

     

     

    • Clinical Trials Market By Phase (USD Billion, 2019-2035)

      • Phase I
      • Phase II
      • Phase III
      • Phase IV

     

    • Clinical Trials Market By Study Design (USD Billion, 2019-2035)

      • Interventional
      • Observational
      • Expanded Access

     

    • Clinical Trials Market By Therapeutic Area (USD Billion, 2019-2035)

      • Oncology
      • Cardiology
      • Neurology
      • Infectious Diseases
      • Endocrinology

     

    • Clinical Trials Market By End Use (USD Billion, 2019-2035)

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials